**Vaishali Pharma Ltd.**
(Formerly known as Vaishali Pharma Pvt. Ltd.)

RATED*
ISO 9001 ISC GLOBAL
GOVT. RECOGNIZED STAR EXPORT HOUSE

CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

24th June, 2020

To,
**National Stock Exchange of India Limited**
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

**Stock Code: VAISHALI**

Dear Sir/Madam,

**Sub: Press Release - Vaishali Pharma forays into the Domestic Formulations & Branded Pharma market with two Dermatological Anti-Fungal Products.**

We refer to captioned subject and wish to inform that the Company has forayed into the Domestic Formulations & Branded Pharma market with launch of two Dermatological Anti-Fungal Products.

| Sr. No. | Brand Name | Product | Usage |
|---|---|---|---|
| 1 | Fungi quick | Itraconazole 100 mg capsules | Anti-fungal |
| 2 | Conazal | Luliconazole 1% cream | Anti-fungal |

Please find enclosed herewith a copy of Press Release giving information about the same.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,
**For Vaishali Pharma Limited**

Atul Arvind Vasani
**Managing Director**

VAISHALI PHARMA LTD. MUMBAI

Vaishali Pharma Limited
CIN: L52310MH2008PLC181632

**June 23, 2020**

**To**
**Corporate Relation Manager,**
**NSE, BKC.**
**Mumbai,**

**Reference: Vaishali Pharma forays into the Domestic Formulations & Branded Pharma market with two Dermatological Anti-Fungal Products**

Vaishali Pharma Ltd is one of the fastest-growing and most versatile companies in the pharmaceutical industry. It is engaged in the manufacturing and marketing of pharmaceuticals formulations, APIs, surgical products, veterinary supplements, herbal, nutraceutical and oncology products. Vaishali has established itself in non-regulated and semi-regulated exports markets for its branded generics, formulations products with presence across 20 countries and around 120 product approvals.

With a successful track record in the exports market, Vaishali Pharma has now forayed into the vast domestic pharmaceutical market. The company has made inroads into the Dermatology therapy segment with launch of two Anti-Fungal Brands:

| Sr. No. | Brand Name | Product | Usage |
|---|---|---|---|
| 1 | Fungi quick | Itraconazole 100 mg capsules | Anti-fungal |
| 2 | Conazal | Luliconazole 1% cream | Anti-fungal |

Derma remains one of the key therapy segments, which has outgrown other therapies consistently. The recent products are targeted to the Dermatologists and General Practitioner's for treating fungal infection. The company is confident of garnering sizeable market share in the products and is likely to add more products to its basket going forward.

Commenting on the launch of these products, Mr. Atul Vasani, Managing Director, Vaishali Pharma said "We are very excited with our foray into the domestic formulations and braded market. We at Vaishali have always strived to innovate and bring affordable Healthcare to the society. We had garnered decent response in the exports market and the launch of our new products in the domestic markets gives us immense pleasure in serving to our own society. We would thrive to bring more value added and innovative products across therapies on a consistent basis in the domestic markets".

## About Vaishali Pharma Limited:

Vaishali Pharma Limited (*NSE: VAISHALI*), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 80 formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers (with around 120 approvals). The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our offices are also located in Kenya, & Vietnam. Further widening our reach overseas, the Company made a joint venture with D.R. Congo based company. The Company exports to countries like Africa, Kenya, Myanmar, Vietnam, Russia etc.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

**For more details please visit:** www.vaishalipharma.com

**For any Investor Relations query, please contact:**

***Mr.Atul Vasani***

***Managing Director***

***Vaishali Pharma Limited***

*Email: director@vaishalipharma.com*

**Note:** *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*